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Abstract 
Objectives 
To determine the psychological response (thoughts, perceptions and affect) to a diagnosis of 
pulmonary nodules following a novel antibody blood test and computed tomography (CT) scans 
within a UK population. 
 
Materials and methods.  
This study was nested within a randomised controlled trial of a blood test (Early CDT®-Lung test), 
followed by a chest x-ray and serial CT-scanning of those with a positive blood test for early 
detection of lung cancer (ECLS Study). Trial participants with a positive Early CDT®-Lung test were 
invited to participate (n=338) and those agreeing completed questionnaires assessing psychological 
outcomes at 1, 3 and 6 months following trial recruitment.  Responses of individuals with pulmonary 
nodules on their first CT scan were compared to those without (classified as normal CT) at 3 and 6 
months follow-up using random effects regression models to account for multiple observations per 
participant, with loge transformation of data where modelling assumptions were not met.  
 
Results 
There were no statistically significant differences between the nodule and normal CT groups in 
affect, lung cancer worry, health anxiety, illness perceptions, lung cancer risk perception or intrusive 
thoughts at  3 or 6 months post-recruitment.  The nodule group had statistically significantly fewer 
avoidance symptoms compared to the normal CT group at 3 months (impact of events scale 
avoidance (IES-A) difference between means -1.99, 95%CI -4.18, 0.21) than at 6 months (IES-A 
difference between means 0.88, 95%CI -1.32, 3.08; p-value for change over time =0.003) with similar 
findings using loge transformed data.  
 
Conclusion 
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A diagnosis of pulmonary nodules following an Early CDT®-Lung test and CT scan did not appear to 
result in adverse psychological responses compared to those with a normal CT scan. 
 
Keywords 
Pulmonary nodules, lung cancer screening, psychological impact 
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Introduction 
Lung cancer is the most common cause of cancer-related deaths worldwide.(1)  During 2014 
approximately 46,400 individuals in the United Kingdom (UK) were diagnosed with lung cancer.(2)  
Despite the incidence of lung cancer decreasing(3), mortality rates remain high, with 1-year survival 
rates ranging from 71% when diagnosed at stage 1 to 16% at stage 4.(4)   
  
The National Lung Screening Trial (NLST), showed serial computed tomography (CT) scanning was 
associated with a 20% reduction in lung cancer mortality.(5)  However, screening has potential 
harms, such as radiation exposure, the detection of non-clinically relevant findings, over-diagnosis 
and psychosocial harms.(6-11)  It is therefore important to ensure acceptability to the population 
being screened(12), and that overall benefits outweigh the harms.(13) 
 
Assessments of the psychosocial impact of lung cancer screening are limited to studies using CT 
scanning.  The NLST, Pittsburgh Lung Screening Study, and the UK Lung Cancer Screening (UKLS) Trial 
found increased anxiety in those with true positive screening results compared to those with 
negative results. The UKLS also found significantly higher cancer worry scale scores 2 weeks after 
receiving CT scan results in those referred for a repeat CT scan compared to those with negative 
results. However, absolute differences were small and not thought to be clinically important. (14-17)  
Additionally, the Dutch-Belgian Randomized Lung Cancer Screening Trial (NELSON trial) and the 
Pittsburgh Lung Screening Study found increased lung cancer specific distress in those with an 
indeterminate result, which diminished over time.(16, 18, 19) 
 
As screening with CT scanning becomes more widespread, more people will be found to have 
incidental findings, such as pulmonary nodules.  Pulmonary nodules are widely defined as round 
lesions within the lung, less than 3cm in diameter and surrounded by normal lung tissue.(20, 21)  
The NLST reported an incidence of pulmonary nodules of 25.9% in participants with a pack year 
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history of at least 30 years.(5)  Several studies used psychological measures to assess the negative 
impact of a diagnosis of pulmonary nodules(22-25), finding increased emotional distress(22, 23), 
frustration and fear (25) amongst those with nodules.  Additionally, French individuals diagnosed 
with pulmonary nodules reported lower health-related quality of life (HRQoL) (measured using the 
SF-36) compared to the French general population.(24)   
 
Our study assesses short and medium-term psychological responses amongst a sample of 
participants, with or without pulmonary nodule(s) identified on their first CT scan, within the Early 
Cancer Detection Test-Lung Cancer Scotland Study (ECLS Study).(26)  This is a randomised controlled 
trial assessing the effectiveness of a blood test for lung cancer screening, measuring autoantibodies 
against seven antigens (Early CDT®-Lung test).(26, 27)  A positive Early CDT®-Lung test is associated 
with a significantly increased risk of malignancy in the presence of pulmonary nodules 4-20mm in 
diameter(28), and the consequent potential for adverse psychological effects.  This study is 
therefore timely in assessing psychological impacts of this test and subsequent CT scanning.  
 
Methods 
This paper presents data on a sub-sample of participants in the ECLS study.  Current or ex-smokers 
aged 50-75 years, with at least 20 pack-years, or fewer pack-years with a first-degree relative with 
lung cancer from Greater Glasgow and Clyde or Tayside, were randomised 1:1 to an Early CDT®-Lung 
test group or a non-screened control group.  All trial participants were asked to complete a baseline 
questionnaire preceding awareness of group allocation.  Those with positive Early CDT®-Lung tests 
were invited for a chest x-ray, followed by a CT scan, and then 6-monthly CT scans for 2 years.  Prior 
to these, they were given information explaining the investigations and the possibility of finding a 
pulmonary nodule on their CT scan.  Individuals were informed of their CT scan result in writing.    
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Participants who had previously consented to be contacted and those with a positive Early 
CDT®-Lung test were invited to participate in this nested psychological outcomes study.  Those 
agreeing completed additional questionnaires at 1, 3, 6, 12, 18 and 24 months collecting data on 
psychological and behavioural outcomes.  Participants were sent a £5 gift voucher for each 
questionnaire completed.  Postal and telephone reminders were used for non-responders.  No 
further questionnaires were sent to participants who were non-responsive to two consecutive 
questionnaires.  On completing the 1-month questionnaire, all participants would have been aware 
that their Early CDT®-Lung test was positive, but 58% of participants had not yet had their CT scan, 
18% had been scanned within the last 7 days, 37% within the last 14 days and 8% more than 14 days 
previously. Consequently, at 1-month follow-up most participants will not have known their CT scan 
results. The analyses presented in this paper are therefore confined to the psychological outcomes 
of Early CDT®-positive group participants who completed baseline and at least one follow-up 
questionnaire at 3 or 6 months.  Participants were categorised into the nodule group if pulmonary 
nodule(s) A? 8mm in diameter were present on their first CT scan and into the normal CT group if they 
were absent (normal CT group participants may have had previously known stable pathology).  Study 
ineligibility criteria can be found in Figure 1. 
  
Data collection 
Baseline information was collected at trial recruitment, between December 2013 and April 2015 and 
included age, gender, smoking history, ethnic group, marital status, postcode, age at leaving full time 
education, employment status, family history of lung cancer (first-degree relative) and 
antidepressant medication use. 
 
Psychological measures included the positive and negative affect schedule (PANAS)(29), lung cancer 
worry scale (LCWS)(30), health anxiety subscale (HAS) of the health orientation scale(31), the impact 
of events scale (IES)(32), the revised illness perception questionnaire-adapted for lung cancer 
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(IPQ-R)(33), and lung cancer risk perception.  The time points at which these were collected, 
descriptions and internal consistency of measures are shown in Supplementary Table 1.  
  
Analysis 
Data analysis was undertaken using Stata Statistical Software version 13.1.(34)  Baseline 
characteristics of those in the normal CT and nodule groups were described using frequencies and 
percentages for categorical data and medians and interquartile ranges (IQR) for non-normally 
distributed continuous data.  For ease of interpretation, means and standard deviations are also 
presented.  Groups were compared using chi-squared tests and Mann-Whitney U tests for 
categorical and continuous variables respectively. &ŝƐŚĞƌ ?ƐĞǆĂĐƚ ƚĞƐƚǁĂƐƵƐĞĚĨŽƌĞƚŚŶŝĐŝƚǇĚƵĞƚŽ
small values.  
 
Multilevel (random effects) regression models were used to compare psychological measures 
between the normal CT and nodule groups over time and to take account of multiple observations 
per participant.  Linear models were used for continuous variables and logistic models for categorical 
variables.  Models were adjusted for study centre, age group (50-54, 55-59, 60-64, 65-69, 70-74, 
75-79 years), sex, smoking status, time (3 and 6 months) and where measured, baseline value of the 
outcome variable.  Analyses were repeated additionally adjusting for baseline antidepressant use 
and family history of lung cancer.  
 
Linearity of continuous covariates was checked by adding higher order terms to models.  Differences 
in outcomes over time between the normal and CT and nodule groups were assessed by adding a 
group by time interaction and using likelihood ratio tests with p<0.01 taken as significant.  
Between-group differences at each time point were estimated from these models. Model 
assumptions were checked by plotting residual values and by excluding observations with large 
residual values (<-3, >3).  Where residuals were not normally distributed or variance was not 
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constant, continuous outcome measures were loge transformed (adding 1 to the IES-I and IES-A 
scores before transformation as some participants scored zero) and model assumptions were 
re-checked.  Where loge transformed models met assumptions better, we present findings on the 
original scale and the loge transformed scale for ease of interpretation.  We were unable to find a 
single standardised method for handling missing data for the psychological measures.  Single missing 
values were therefore replaced with the mean or subscale score for the participant for PANAS, HAS, 
LCWS Impact Score and IES.  When more than one value was missing the scale score was considered 
to be missing.   
 
Results 
Three hundred and thirty eight Early CDT®-Lung test-positive ECLS trial participants took part in the 
psychological outcomes study, 269 (174 in the normal CT group and 95 in the nodule group) of 
whom were eligible to be included in the analyses presented in this paper (Figure 1).  Response rates 
to follow-up questionnaires were high.  The analysis included 95% at 3 months and 94% at 6 months.    
All participants were aware of their CT scan result on completing the 3-month questionnaire. 
 
Baseline demographic and psychological measures 
Table 1 shows baseline demographic characteristics by nodule status.  There were no statistically 
significant differences between the nodule and normal CT groups. Psychological measures at 
baseline are shown in Table 2.  The only statistically significant difference was that nodule group 
participants had significantly higher (P=0.04) positive affect PANAS scores than normal CT group 
participants (median (IQR) 37.4 (27, 41.6) vs. 32 (26.7, 39)).   
 
Psychological measures at 3 and 6 months follow-up 
Psychological measure scores at 3 and 6 months are shown in Table 3 and Table 4 shows adjusted 
differences between means and odds ratios comparing the nodule to the normal CT group at 3 and 6 
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months.  The nodule group had statistically significantly fewer avoidance symptoms compared to the 
normal CT group at 3 months (difference between means in impact of events scale avoidance (IES-A) 
score -1.99, 95%CI -4.18, 0.21) than at 6 months (difference between means in IES-A score 0.88, 
95%CI -1.32, 3.08; P-value for change over time=0.003). However, the differences in means between 
the nodule and normal CT groups were small at both time points.  Table 5 shows differences 
between the means of loge transformed data for outcomes where model assumptions were better 
met using transformed data. Findings were similar to those using data on the original scale with 
lower IES-A scores in the nodule than the normal CT group at 3 months (difference in loge 
transformed means  
-0.34 (-0.65, -0.04) than at 6 months (difference in loge transformed means -0.06 (-0.36, 0.24)) but 
the change over time did not reach statistical significance (P=0.04).  No other statistically significant 
differences between means or odds ratios were seen over time.  Adjusting the models for whether 
participants took antidepressant medication at baseline or had a family history of lung cancer had 
little impact on the findings.  Models were robust to exclusion of observations with large residual 
values.   
 
Discussion 
Summary 
This study demonstrates that a diagnosis of pulmonary nodules on a CT scan following an Early 
CDT®-Lung positive result for lung cancer screening does not result in an adverse psychological 
response in relation to affect, health anxiety, thought intrusion and illness perception compared to 
those who had a normal CT scan in both the short and medium-term.  Although those in the nodule 
group had statistically significantly fewer avoidance behaviours than those in the normal CT group at 
3 months than at 6 months, the differences between the mean scores in the nodule and normal CT 
groups were small at both time points.   
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Strengths and limitations 
To our knowledge, this is the first study examining the psychological impact of receiving a pulmonary 
nodule diagnosis following a novel antibody test and chest CT scan within a UK population.  
Strengths of our study include use of a range of psychological outcome measures, which included 
positive as well as negative psychological responses, measures were repeated at multiple time 
points, a very high follow-up rate and analyses were adjusted for baseline measures where possible.  
However, it is possible that there may be small but potentially clinically important differences, which 
we did not have sufficient power to detect.  Although a lower p-value (0.01) was used for 
significance testing of changes in scores between groups over time, multiple significance testing may 
have resulted in significant findings for the IES avoidance score.  However, even if our IES Avoidance 
score findings are not due to type 1 error, differences in mean scores between the nodule and 
normal CT group were small and unlikely to be clinically meaningful.(18)  As we did not know 
whether participants had received their CT scan result at the time of completing the 1-month 
questionnaire,  this study does not evaluate the immediate response to receiving a pulmonary 
nodule diagnosis. 
 
Comparison with existing literature 
Previous studies examining the psychological impact of a pulmonary nodule diagnosis have found 
contrasting results.(18, 19, 24, 35, 36)  Two studies in America found that individuals diagnosed with 
pulmonary nodules reported emotional distress (measured using the IES) shortly after diagnosis 
(time not specified)(35) and up to 2 or more years after diagnosis (19, 36).These findings differ from 
our study and those of the NELSON trial, with the latter showing an early (2 months after 
diagnosis)(18) and temporary clinically important increase in IES scores in individuals with 
nodules.(19)  Additionally, the NELSON trial did not find that health-related quality of life (HRQoL) 
was affected by a pulmonary nodule diagnosis (19), which contrasts with a study in France.(24) This 
found a significantly lower HRQoL at 6-months post-diagnosis in those with pulmonary nodules 
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compared to the French general population.(24) There are multiple factors that could explain the 
differences seen between these studies and ours.  These include differences in screening procedures 
(our study used the Early CDT®-Lung test to identify those for CT scanning whereas other studies 
used CT screening alone or included participants found to have pulmonary nodules during routine 
clinical care), study populations, timing of questionnaire administration, definitions of pulmonary 
nodules, mode of nodule detection (screened versus incidentally detected), whether the study 
compared to a control group and whether adjustments were made for baseline measures.  
Additionally, our study participants received information explaining pulmonary nodules prior to their 
radiological investigations and enclosed with their CT scan results. 
  
It is not possible to directly equate the findings of this study with those of the UKLS, which did not 
compare individuals with pulmonary nodules to those with a normal CT.(15, 17)  Participants with 
pulmonary nodules will have been included in the UKLS  “ƌĞƉĞĂƚƐĐĂŶƌĞƋƵŝƌĞĚŐƌŽƵƉ ?ĨŽƌƚŚĞ ?-week 
ŽƵƚĐŽŵĞƐ ĂŶĂůǇƐŝƐ ĂŶĚ ŝŶ ƚŚĞ  “ĨĂůƐĞ ƉŽƐŝƚŝǀĞ ? ŐƌŽƵƉ ĨŽƌ ƚŚĞ up to 2-years outcome analysis.   A 
statistically significant, but not clinically important, increase in lung cancer worry was found at 2 
weeks in those needing repeat scans compared to those with a negative CT scan result. No other 
statistically significant or clinically important differences were found in lung cancer worry, anxiety or 
depression at 2 weeks or up to 2 years, which is consistent with our findings.   
 
There are several potential explanations for our finding that participants in the nodule group had a 
more positive psychological response (lower avoidance scores) than the normal CT group. It is 
possible that receiving a positive Early CDT®-Lung test psychologically prepared participants to 
receive an abnormal CT scan result, leading to a more positive psychological response than in studies 
where the CT scan is the first abnormal result a participant receives. Furthermore, receiving a 
diagnosis of pulmonary nodules after a positive Early CDT®-Lung test may have provided participants 
with reassurance, as ƚŚŝƐŵĂǇďĞƉĞƌĐĞŝǀĞĚĂƐĂŶ “ĞǆƉůĂŶĂƚŝŽŶ ?ĨŽƌƚŚĞƉŽƐŝƚŝǀĞEarly CDT®-Lung test, 
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whilst those with a normal CT scan may have interpreted this as contradictory to the blood test 
finding, and experienced a lack of reassurance. It is also possible that participants with a positive 
Early CDT®-Lung test were preparing themselves psychologically to receive a CT result suspicious for 
lung cancer, and a diagnosis of pulmonary nodules may have been perceived as a much more 
favourable outcome, with a more positive psychological response. The manner in which the CT 
results were communicated may also have been important in determining the psychological 
response. Those with pulmonary nodules were sent their results by letter. This said the scan was 
satisfactory but had shown small nodules within one of the lungs which were less than 8mm in size 
and were most likely to be of little health concern. The letter also offered the option to discuss their 
scan results face-to-face with a doctor from the study team.  In addition, participants were advised 
that the nodules would be monitored with further CT scans and any changes in nodules would result 
in a face-to-face discussion with a doctor. There was a also a small but statistically significant 
difference in positive affect scores at baseline, with the nodule group having a higher score than 
those with a normal CT. Higher positive affect scores have been associated with a lower incidence of 
psychological illness,(37) so this may also potentially explain our finding of lower avoidance scores in 
those with nodules than in those with a normal CT at 3 months. 
 
 Implications for research and practice 
Our findings provide some reassurance to clinicians concerned about the potential harms of lung 
cancer screening using a novel blood antibody test followed by serial CT scanning, should it be more 
widely implemented.  There is likely to be little impact on health services in terms of emotionally 
distressed patients seeking help after pulmonary nodules being found on screening CT scans.  
Further work is required to explore the short-term impact (i.e. within a month) of a diagnosis of 
ƉƵůŵŽŶĂƌǇ ŶŽĚƵůĞƐ ŝŶ ƚŚĞ ĐŽŶƚĞǆƚ ŽĨ Ă ƐĐƌĞĞŶŝŶŐ ƉƌŽŐƌĂŵŵĞ ĂŶĚ ƉĂƚŝĞŶƚƐ ? ƵŶĚĞƌƐƚĂŶĚŝŶŐ ŽĨ ƚŚĞ
results of both blood tests and CT scans, and the impact of their understanding on psychological 
responses.  
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Figure 1. Number of ECLS participants eligible for inclusion within the study at each questionnaire 
time-point. 
 
Table 1. Psychological measures included in the questionnaires, with a brief description of each 
measure. 
 
Table 2. Demographic characteristics at baseline amongst participants in the nodule group and those 
in the normal CT group (% indicates column percentage unless otherwise stated). 
 
Table 3. Psychological measures at baseline amongst participants in the nodule group and those in 
the normal CT group (% indicates column percentage unless otherwise stated). 
 
Table 4. Psychological measures at 1, 3 and 6 months amongst participants in the nodule group and 
those in the normal CT group (% indicates column percentage unless otherwise stated). 
 
Table 5. Difference between means and odds ratios for psychological measures at 1, 3 and 6 months 
comparing participants in the nodule group to those in the normal CT group. 
 Figure 1. Number of ECLS participants eligible for inclusion within the study at each questionnaire time-point. 
*these participants were also sent the next follow-up questionnaire 
Figure
Table 1. Demographic characteristics at baseline amongst participants in the nodule group and those in the 
normal CT group (% indicates column percentage unless otherwise stated). 
Variable 
Nodule Normal CT 
Statistical Test 
n = 95 (%) n = 174 (%) 
Study Centre 
Glasgow 
Tayside 
  
72 (75.8) 
23 (24.2) 
  
123 (70.7) 
51 (29.3) 
  
ʖ ?(1) = 0.80, p = 0.37 
Age (years - median (IQR*))  
50-54 years 
55-59 years 
60-64 years 
65-69 years 
70-74 years 
75-79 years 
61 (56, 67) 
17 (17.9) 
22 (23.2) 
21 (22.1) 
23 (24.2) 
12 (12.6) 
0 (0) 
60 (55, 66) 
37 (21.3) 
48 (27.6) 
31 (17.8) 
40 (23.0) 
15 (8.6) 
3 (1.7) 
z = -1.30, p = 0.19 
ʖ ?(5) = 4.06, p = 0.54  
  
  
  
Gender 
Male 
Female 
  
39 (41.1) 
56 (58.9) 
  
80 (46.0) 
94 (54.0) 
  
ʖ ?(1) = 0.60, p = 0.44 
Smoking Status 
Current smoker 
Ex-smoker 
  
50 (52.6) 
45 (47.4) 
  
88 (50.6) 
86 (49.4) 
  
ʖ ?(1) = 0.10, p = 0.75 
Smoking Pack-year (median (IQR)) 35 (26, 48) 32.5 (25, 49) z = -0.83, p = 0.41 
Ethnic Origin 
White British 
Other  
[0] 
93 (97.9) 
 2 (2.1) 
[4] 
165 (97.1) 
5 (2.9) 
  
&ŝƐŚĞƌ ?ƐĞǆĂĐƚp = 1.00 
  
Marital Status 
Single 
In a relationship/married/civil partnership 
Widowed 
Separated/divorced 
[0] 
5 (5.3) 
67 (70.5) 
10 (10.5) 
13 (13.7) 
[5] 
15 (8.9) 
103 (61.0) 
17 (10.0) 
34 (20.1) 
  
ʖ ?(3) = 3.34, p = 0.34 
Scottish Index of Multiple Deprivation (Rank) 
1-1395 (most deprived) 
1396-2790 
2791-4186 
4187-5581 
5582-6976 (least deprived) 
  
35 (36.8) 
27 (28.4) 
14 (14.7) 
8 (8.4) 
11 (11.6) 
  
68 (39.1) 
42 (24.1) 
27 (15.5) 
23 (13.2) 
14 (8.1) 
  
ʖ ?(4) = 2.60, p = 0.63 
  
  
  
  
Prescribed medication for low mood 
Yes 
No 
[1] 
11 (11.7) 
83 (88.3) 
[4] 
30 (17.7) 
140 (82.4) 
  
ʖ ?(1) = 1.63, p = 0.20 
  
Age at leaving full-time education (years - 
median (IQR))  
[2] 
16 (15, 16) 
[7] 
16 (15, 16) 
  
z = 0.29, p = 0.77 
Work Status 
Employed 
Unemployed  
Retired/other 
[0] 
40 (42.1) 
16 (16.8) 
39 (41.1) 
[5] 
75 (44.4) 
33 (19.5) 
61 (36.1) 
  
ʖ ?(2) = 0.70, p = 0.70 
First degree relative with lung cancer 
No 
Yes 
  
70 (73.7) 
25 (26.3) 
  
115 (66.1) 
59 (33.9) 
  
ʖ ?(1) = 1.65, p = 0.20 
[missing values] *Interquartile range  
Table
 Table 2. Psychological measures at baseline amongst participants in the nodule group and those in the normal 
CT group (% indicates column percentage unless otherwise stated). 
 
Psychological Measure Nodule 
n = 95 (%) 
Normal CT 
n = 174 (%) 
Statistical 
Test 
Positive and Negative Affect Schedule (PANAS) 
Positive affect score (median (IQR*)) 
(mean (SD**)) 
Negative affect score (median (IQR)) 
(mean (SD)) 
[3] 
37.4 (27, 41.6) 
34.5 (9.2) 
13 (11, 18) 
15.6 (6.4) 
[5] 
32 (26.7, 39) 
32.4 (8.8) 
13 (11, 18) 
15.7 (6.5) 
  
z = -2.02 
p = 0.04 
z = -0.06 
p = 0.96  
Lung Cancer Worry Scale 
How worried are you about getting lung cancer someday? 
Not worried 
Worried 
What is your current anxiety level about the results of 
future tests/treatments? 
Not anxious 
Anxious 
Impact of worry  
Median (IQR) 
(mean (SD)) 
  
[2] 
46 (49.5) 
47 (50.5) 
 
[2] 
87 (93.6) 
6 (6.4) 
[2] 
2 (2, 3) 
2.9 (1.3) 
  
[2] 
66 (38.4) 
106 (61.6) 
 
[2] 
153 (89.0) 
 19 (11.0) 
[2] 
3 (2, 3) 
3.0 (1.4) 
  
  
ʖ ?(1) = 3.04 
p = 0.08 
  
 
ʖ ?(1) = 1.49 
p = 0.22 
 
z = 1.44 
p = 0.15 
Illness Perception Questionnaire (IPQ-R) 
What I do can affect my risk of getting lung cancer 
Agree 
Disagree 
When I think about my risk of getting lung cancer I get 
upset 
Agree 
Disagree 
I do not know how likely it is that I might get lung cancer 
Agree 
Disagree 
Finding lung cancer early can improve my chances of 
survival 
Agree 
Disagree 
Lung cancer would have a big impact on my life 
Agree 
Disagree 
Lung cancer lasts for a long time 
Agree 
Disagree 
A blood screening test can accurately detect lung cancer 
Agree 
Disagree 
  
[1] 
85 (90.4) 
9 (9.6) 
[1] 
43 (45.7) 
51 (54.3) 
[2] 
60 (64.5) 
33 (35.5) 
[2] 
88 (94.6) 
5 (5.4) 
[2] 
89 (95.7) 
4 (4.3) 
[2] 
60 (64.5) 
33 (35.5) 
[1] 
60 (63.8) 
34 (36.2) 
  
[4] 
153 (90.0) 
17 (10.0) 
[4] 
78 (45.9) 
92 (54.1) 
[6] 
116 (66.7) 
56 (33.3) 
[2] 
165 (95.9) 
7 (4.1) 
[3] 
167 (97.7) 
4 (2.3) 
[2] 
106 (61.6) 
66 (38.4) 
[3] 
106 (62.0) 
65 (38.0) 
  
  
ʖ ?(1) = 0.01 
p = 0.91 
  
ʖ ?(1) = 0.001 
p = 0.98 
 
ʖ ?(1) = 0.12 
p = 0.73 
   
ʖ ?(1) = 0.24 
p = 0.63 
  
ʖ ?(1) = 0.79 
p = 0.37 
   
ʖ ?(1) = 0.22 
p = 0.64 
   
ʖ ?(1) = 0.09 
p = 0.77 
Lung Cancer Risk Perception 
What are the chances that you will develop lung cancer 
over the next 5 years? 
A? ? ? ?A? ?ůŽǁƌŝƐŬ ? ?ŽŶ ?ƚŬŶŽǁ 
A? ?A? ?ŚŝŐŚƌŝƐŬ ? 
Compared to other people of your age and sex, how likely 
are you to develop lung cancer over the next 5 years? 
Less likely/Don't know 
More likely  
  
[0] 
85 (89.5) 
10 (10.5) 
 
[0] 
 
50 (52.6) 
45 (47.4) 
  
[2] 
153 (89.0) 
19 (11.0) 
 
[2] 
 
82 (47.7) 
90 (52.3) 
  
  
ʖ ?(1) = 0.02 
 p = 0.90 
  
  
 
ʖ ?(1) = 0.60 
p = 0.44 
[Missing values] *Interquartile range **Standard deviation 
Table
Table 3. Psychological measures at 3 and 6 months amongst participants in the nodule group and those in the normal CT group (% indicates column percentage unless 
otherwise stated). 
Psychological Measure 3 months 6 months 
 Nodule 
n=91 (%) 
Normal CT 
n=165 (%) 
Nodule 
n=91 (%) 
Normal CT 
n=163 (%) 
Positive and Negative Affect Schedule (PANAS) 
Positive affect score  
Median (IQR*) 
(mean (SD**)) 
Negative affect score 
Median (IQR) 
(mean (SD)) 
 
[1] 
32.5 (25-40) 
32.1 (10.0) 
[1] 
14 (11, 22) 
16.7 (7.6) 
 
[3] 
30 (24-35) 
29.3 (8.5) 
[3] 
13 (11, 20) 
16.8 (8.0) 
 
[1] 
34.5 (26-40) 
32.8 (10.2) 
[1] 
14 (10, 21) 
16.4 (7.8) 
 
[2] 
30 (23-36) 
29.7 (9.2) 
[2] 
14 (11, 20) 
16.5 (7.1) 
Lung Cancer Worry Scale 
How worried are you about getting lung cancer someday? 
Not worried 
Worried 
What is your current anxiety level about the results of future 
tests/treatments? 
Not anxious 
Anxious 
Impact of worry  
Median (IQR) 
(mean (SD)) 
 
[0] 
39 (42.9) 
52 (57.1) 
 
[1] 
73 (81.1) 
17 (18.9) 
[1] 
3 (2, 4) 
3.3 (1.7) 
 
[0] 
62 (37.6) 
104 (62.4) 
 
[0] 
133 (80.6) 
32 (19.4) 
[1] 
3 (2, 4) 
3.4 (1.7) 
 
[0] 
39 (42.9) 
52 (57.1) 
 
[1] 
71 (78.9) 
19 (21.1) 
[2] 
2 (2, 4) 
3.2 (1.7) 
 
[0] 
56 (34.4) 
107 (65.6) 
 
[1] 
132 (81.5) 
30 (18.5) 
[1] 
3 (2,4) 
3.4 (1.7) 
Illness Perception Questionnaire (IPQ-R) 
What I do can affect my risk of getting lung cancer 
Agree 
Disagree 
When I think about my risk of getting lung cancer I get upset 
Agree 
Disagree 
I do not know how likely it is that I might get lung cancer 
Agree 
Disagree 
Finding lung cancer early can improve my chances of survival 
Agree  
Disagree 
 
[1] 
80 (88.9) 
10 (11.1) 
[1] 
39 (43.3) 
51 (56.7) 
[2] 
53 (59.5) 
36 (40.5) 
[0] 
86 (94.5) 
5 (5.5) 
 
[3] 
147 (90.7) 
15 (9.3) 
[3] 
71 (43.8) 
91 (56.2) 
[3] 
95 (58.6) 
67 (41.4) 
[2] 
152 (93.3) 
11 (6.7) 
 
[0] 
84 (92.3) 
7 (7.7) 
[1] 
42 (46.7) 
48 (53.3) 
[2] 
40 (44.9) 
49 (55.1) 
[0] 
84 (92.3) 
7 (7.7) 
 
[2] 
147 (91.3) 
14 (8.7) 
[1] 
75 (46.3) 
87 (53.7) 
[1] 
89 (54.9) 
73 (45.1) 
[0] 
151 (92.6) 
12 (7.4) 
Table
Lung cancer would have a big impact on my life 
Agree 
Disagree 
Lung cancer lasts for a long time 
Agree 
Disagree 
A blood screening test can accurately detect lung cancer 
Agree  
Disagree 
[0] 
87 (95.6) 
4 (4.4) 
[0] 
56 (61.5) 
35 (38.5) 
[2] 
52 (58.4) 
37 (41.6) 
[1] 
157 (95.7) 
7 (4.3) 
[3] 
98 (60.5) 
64 (39.5) 
[3] 
92 (56.8) 
70 (43.2) 
[1] 
86 (95.6) 
4 (4.4) 
[1] 
51 (56.7) 
39 (43.3) 
[0] 
49 (53.9) 
42 (46.2) 
[1] 
156 (96.3) 
6 (3.7) 
[3] 
91 (56.9) 
69 (43.1) 
[0] 
81 (49.7) 
82 (50.3) 
Lung Cancer Risk Perception 
What are the chances that you will develop lung cancer over the next 5 
years? 
A? ? ? ?A? ?ůŽǁƌŝƐŬ ? ?ŽŶ ?ƚŬŶŽǁ 
A? ?A? ?ŚŝŐŚƌŝƐŬ ? 
Compared to other people of your age and sex, how likely are you to develop 
lung cancer over the next 5 years? 
Less likely / Don't know 
More likely 
 
 
[0] 
65 (71.4) 
26 (28.6) 
 
[0] 
37 (40.7) 
54 (59.3) 
 
 
0] 
118 (71.5) 
47 (28.5) 
 
[1] 
57 (34.8) 
107 (65.2) 
 
 
[1] 
61 (67.8) 
29 (32.2) 
 
[0] 
31 (34.1) 
60 (65.9) 
 
 
[0] 
121 (74.2) 
42 (25.8) 
 
[0] 
64 (39.3) 
99 (60.7) 
Health Anxiety Subscale (HAS)  
Median (IQR) 
(mean (SD)) 
[0] 
5 (3, 10) 
7.2 (5.7) 
[0] 
6 (4, 11) 
8.0 (5.3) 
[0] 
5 (3, 9) 
7.0 (5.8) 
[0] 
6 (3, 12) 
7.8 (5.5) 
Impact of Events Scale 
Intrusion score  
Median (IQR) 
(mean (SD)) 
Avoidance score 
Median (IQR) 
(mean (SD)) 
 
[1] 
0.5 (0, 6) 
4.2 (6.9) 
[1] 
0.5 (0, 5) 
4.7 (8.2) 
 
[0] 
2 (0, 7) 
4.7 (6.6) 
[0] 
2 (0, 10) 
6.4 (8.8) 
 
[0] 
0 (0, 6) 
4.1 (6.8) 
[0] 
0 (0, 13) 
6.8 (10.7) 
 
[1] 
0 (0, 6) 
3.8 (6.4) 
[3] 
1 (0, 8.5) 
5.4 (8.3) 
[Missing values] *Interquartile range **Standard deviation 
Table 4. Difference between means and odds ratios for psychological measures at 3 and 6 months comparing 
participants in the nodule group to those in the normal CT group. 
Psychological Measure Difference 
between means 
(95 %CI) at 3 months 
Difference 
between means 
(95 %CI) at 6 months 
P-value for 
difference 
between means 
over time 
Positive and Negative Affect Schedule (PANAS)       
Positive affect score* 1.17 (-0.67, 3.01) 1.46 (-0.39, 3.30) P = 0.76 
Negative affect score* 0.13 (-1.34, 1.60) -0.05 (-1.52, 1.42) P = 0.79 
Lung Cancer Worry Scale       
Impact of worry * -0.01 (-0.39, 0.37) -0.15 (-0.53, 0.24) P = 0.36 
Health Anxiety Subscale (HAS)** -1.00 (-2.35, 0.35) -0.83 (-2.18, 0.52) P = 0.71 
Impact of Events Scale       
Intrusion score** -0.73 (-2.37, 0.91) -0.24 (-1.88, 1.40) P = 0.45 
Avoidance score** -1.99 (-4.18, 0.21) 0.88 (-1.32, 3.08) P = 0.003 
  Odds ratios  
(95 %CI) at 3 months 
Odds ratios  
(95 %CI) at 6 months 
P-value for 
difference 
between odds 
ratios over time 
Lung Cancer Worry Scale       
How worried are you about getting lung cancer 
someday?* (worried vs. not worried) 
1.07 (0.32, 3.53) 0.63 (0.19,2.13) P = 0.41 
What is your current anxiety level about the results 
of future tests/treatments?* (anxious vs. not 
anxious) 
1.09 (0.31, 3.85) 1.42 (0.41, 4.92) P = 0.70 
Illness Perception Questionnaire  
(IPQ-LC)  
      
What I do can affect my risk of getting lung cancer* 
(agree vs. disagree) 
0.79 (0.29, 2.16) 1.20 (0.40, 3.61) P = 0.56 
When I think about my risk of getting lung cancer I 
get upset* (agree vs. disagree) 
0.80 (0.18, 3.51) 0.87 (0.20, 3.81) P = 0.90 
I do not know how likely it is that I might get lung 
cancer* (agree vs. disagree) 
1.13 (0.51, 2.51) 0.57 (0.26, 1.26) P = 0.15 
Finding lung cancer early can improve my chances of 
survival* (agree vs. disagree) 
1.39 (0.33, 5.93) 0.85 (0.22, 3.26) P = 0.58 
Lung cancer would have a big impact on my life** 
(agree vs. disagree) 
1.17 (0.15, 8.91) 0.78 (0.10, 6.11) P = 0.72 
Lung cancer lasts for a long time* (agree vs. disagree) 1.14 (0.40, 3.22) 0.86 (0.31, 2.42) P = 0.61 
A blood screening test can accurately detect lung 
cancer* (agree vs. disagree) 
1.33 (0.42, 4.17) 1.58 (0.51, 4.92) P = 0.76 
Lung Cancer Risk Perception       
What are the chances that you will develop lung 
cancer over the next 5 years?* (high vs. low) 
0.85 (0.25, 2.91) 1.85 (0.54, 6.33) P = 0.21 
Compared to other people of your age and sex, how 
likely are you to develop lung cancer over the next 5 
years?* (more vs. less) 
0.75 (0.32, 1.77) 1.63 (0.68, 3.91) P = 0.13 
*Adjusted for study centre, age group, gender, smoking status, time and baseline.     
**Adjusted for study centre, age group, gender, smoking status and time.     
Table
Table 5. Difference between loge transformed means for continuous psychological measures at 3 and 6 
months comparing participants in the nodule group to those in the normal CT group. 
 
Psychological Measure Difference 
between loge 
transformed 
means 
(95 %CI) at 3 
months 
Difference 
between loge 
transformed 
means 
(95 %CI) at 6 
months 
P-value for 
difference 
between loge 
transformed 
means over time 
Negative Affect Schedule (PANAS)* 0.005 (-0.07, 0.08) -0.02 (-0.10, 0.06) p = 0.50 
Lung Cancer Worry Scale* -0.004 (-0.10, 0.09) -0.05 (-0.15, 0.04) p = 0.23 
Health Anxiety Subscale (HAS)** -0.20 (-0.40, 0.01) -0.17 (-0.38, 0.03) p = 0.76 
Impact of Events Scale ʹ Intrusion Score** -0.20 (-0.48, 0.07) -0.09 (-0.36, 0.18) p = 0.34 
Impact of Events Scale ʹ Avoidance Score** -0.34 (-0.65, -0.04) -0.06 (-0.36, 0.24) p = 0.04 
*Adjusted for study centre, age group, gender, smoking status, time and baseline.   
**Adjusted for study centre, age group, gender, smoking status and time. 
Table
Supplementary table 1. Psychological measures included in the questionnaires, with a brief description of each measure. 
 
Psychological Measure Administered 
at baseline 
Administered 
at 1, 3 & 6 
months 
Description References 
Positive and negative affect schedule 
(PANAS) 
Positive affect score 
Negative affect score 
9 
  
  
9 
  
  
Two 10-item scales containing positive 
and negative statements, with 5-point 
Likert scale (1-5) responses to give a score 
for each scale of 10-50*. ƌŽŶďĂĐŚ ?ƐĂůƉŚĂ
for positive and negative scales ranges 
from 0.84-0.90 dependent on the 
ƌĞƉŽƌƚŝŶŐƉĞƌŝŽĚƵƐĞĚ ?ƌĂŶŐŝŶŐĨƌŽŵ “Ăƚ
ƚŚĞŵŽŵĞŶƚ ?ƚŽ “ŝŶŐĞŶĞƌĂů ? ? ?   
Watson D, Clark LA, Tellegen A. Development and validation of 
brief measures of positive and negative affect: The PANAS 
scales. Journal of Personality and Social Psychology. 
1988;54(6):1063-70. 
 
Crawford JR, Henry JD. The positive and negative affect 
schedule (PANAS): construct validity, measurement properties 
and normative data in a large non-clinical sample. The British 
journal of clinical psychology / the British Psychological Society. 
2004;43(Pt 3):245-65. Epub 2004/08/31. 
Lung cancer worry scale (LCWS)  
1) How worried are you about getting lung 
cancer someday? 
2) How much does your worry affect your 
mood? 
3) How much does your worry affect your 
ability to perform your daily activities? 
4) What is your current anxiety level about 
the results of future tests/treatments? 
9 
  
  
  
  
9 
  
  
  
  
Modified from the cancer worry scale by 
changing breast cancer to lung cancer and 
by changing mammograms to future 
tests/treatments. Four questions with 5-
point Likert scale responses. Questions 2 
and 3 were combined to give an impact of 
worry score (range 2-10)*. Answers to 
questions 1 and 4 were dichotomised as 
"not worried" vs. "worried" and "not 
anxious" vs. "anxious". "Sometimes" 
responses were categorised as "worried" 
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scale used in relation to breast and 
prostate cancer ranges from 0.71 to 0.86. 
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Health anxiety subscale (HAS)  9 One of ten subscales of the health 
orientation scale measuring presence of 
anxious feelings associated with a 
person's physical health.  Five questions 
with 5-point Likert scale (0-4) responses to 
Snell WE, Johnson G, Lloyd PJ, Hoover MW. The Health 
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give a score of 0- ? ? ? ?ƌŽŶďĂĐŚ ?ƐĂůƉŚĂ
=0.82. 
Impact of events scale (IES) 
1) Intrusion score 
2) Avoidance score 
 9 
  
  
Adapted from the original scale used for 
bereaved individuals by changing the 
ƌĞĨĞƌĞŶƚĞǀĞŶƚƚŽ “ďĞŝŶŐƚĞƐƚĞĚĨŽƌlung 
ĐĂŶĐĞƌ ? ?&ŝĨƚĞĞŶƋƵĞƐƚŝŽŶƐĐŽǀĞƌĞĚ
intrusive thoughts and avoidant behaviour 
following lung cancer screening, with 4-
point Likert scale (0-3) responses to give 
an avoidance score ranging from 0-24* 
and an intrusion score ranging from 0-21*. 
ƌŽŶďĂĐŚ ?Ɛ alpha for the original scale 
=0.78 for the intrusion score and 0.82 for 
the avoidance score. 
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1979;41(3):209-18. Epub 1979/05/01. 
 
 
Illness perception questionnaire (IPQ-R) 
1) What I do can affect my risk of getting 
lung cancer 
2) When I think about my risk of getting 
lung cancer I get upset 
3) I do not know how likely it is that I might 
get lung cancer 
4) Finding lung cancer early can improve my 
chances of survival 
5) Lung cancer would have a big impact on 
my life 
6) Lung cancer lasts for a long time 
7) A blood screening test can accurately 
detect lung cancer 
9 9 Based on the revised illness perception 
questionnaire, assessing emotional 
response generated by illness. Seven 
questions, each selected as the item with 
the highest factor loading in each subscale 
in a study of ovarian cancer screening, 
with 5-point Likert scale (1-5) responses. 
Answers were dichotomised to "agree" vs. 
"disagree". "Neutral" responses were 
categorised as "disagree." ƌŽŶďĂĐŚ ?Ɛ
alpha for the subscales ranges from 0.79-
0.89.  
Moss-Morris R, Weinman J, Petrie K, Horne R, Cameron L, Buick 
D. The Revised Illness Perception Questionnaire (IPQ-R). 
Psychology & Health. 2002;17(1):1-16. 
 
Lancastle D, Brain K, Phelps C. Illness representations and 
distress in women undergoing screening for familial ovarian 
cancer. Psychology & Health. 2011;26(12):1659-77. 
Lung cancer risk perception 
1) Absolute risk (What are the chances that 
you will develop lung cancer over the next 5 
years?) 
2) Relative risk (Compared to other people 
of your age and sex, how likely are you to 
develop lung cancer over the next 5 years?) 
9 9 Assessed awareness of risk of developing 
lung cancer. Absolute risk responses 
ƌĂŶŐĞĚĨƌŽŵ ?ŝŶ ? ? ? ?ƚŽA䠀  ?ŝŶ ? ? ?ĚŽŶ ?ƚ
know option included), dichotomised to 
"low risk" (1 in 1000 to 1 in 250 and don't 
know) vs. "high risk" (1 in 100 to 1 in 10).  
Relative risk was assessed using 6 possible 
responses (don't know option included) 
ranging from a lot less likely to much more 
likely, dichotomised to "less likely" vs. 
"more likely." Don't know responses were 
categorised as "less likely."    
Questions developed for the ECLS study. 
*Higher score indicates a greater degree of the psychological outcome. 
